Detalhe da pesquisa
1.
A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications.
BMC Bioinformatics
; 22(1): 102, 2021 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33653269
2.
LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency.
Cancer Res Commun
; 4(5): 1199-1210, 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630886
3.
LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.
Oncotarget
; 14: 597-611, 2023 06 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306526
4.
Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma.
Clin Cancer Res
; 29(20): 4209-4218, 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37494541
5.
Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies.
Mol Cancer Ther
; 22(10): 1182-1190, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552607
6.
The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.
Oncotarget
; 12(8): 791-806, 2021 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33889302
7.
Addendum: LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.
Oncotarget
; 14: 722, 2023 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37477520